Prediction of the Efficacy of Activated Recombinant Human Factor VII in Adult Congenital Haemophilia A or B Patients With Inhibitors by Use of Thromboelastography

Inclusion Criteria

• •Confirmed diagnosis of congenital haemophilia A or B with a FVIII:C clot activity or FIX:C clot activity, respectively, less than 5%
• •Presently use of activated recombinant human factor VII (NovoSeven®) as haemostatic agent for preventive treatment or treatment of bleeding episodes
• •A documented historical or present record for the presence of inhibitors to factor VIII or IX, respectively
• •A documented history of 2 or more joint bleeding episodes during the preceding 12 months
• •Subjects must be in a non-bleeding state (i.e. no clinical manifestations of active bleeds)